Novartis Announces Its Data From Phase III NATALEE Study Demonstrates Kisqali Eliminates Risk Of Death By ~20% In Patients With Stage II And III HR+/Her2- Early Breast Cancer

Benzinga · 2d ago

https://www.novartis.com/news/media-releases/kisqali-shows-clinically-meaningful-overall-survival-broadest-hrher2-early-breast-cancer-population-high-risk-recurrence